natgillin/translations-raw huggingface dataset:
It is thought that olanzapine’s beneficial effect is due to it blocking receptors for the neurotransmitters 5- hydroxytrypamine (also called serotonin) and dopamine.
Domneva se, da so koristni učinki olanzapina posledica zaviranja receptorjev za živčna prenašalca 5-hidroksitripamin (imenovanega tudi serotonin) in dopamin.
It is thought that olanzapine’s beneficial effect is due to it blocking receptors for the neurotransmitters 5-hydroxytrypamine (also called serotonin) and dopamine.
Domneva se, da so koristni učinki olanzapina posledica zaviranja receptorjev za živčna prenašalca 5- hidroksitripamin (imenovanega tudi serotonin) in dopamin.
It is thought that olanzapine’s beneficial effect is due to it blocking receptors for the neurotransmitters 5-hydroxytryptamine (also called serotonin) and dopamine.
Domneva se, da so koristni učinki olanzapina posledica blokiranja receptorjev za živčna prenašalca 5-hidroksitriptamin (imenovan tudi serotonin) in dopamin.
It is thought that olanzapine’s beneficial effect is due to it blocking receptors for the neurotransmitters 5-hydroxytryptamine (also called serotonin) and dopamine.
Domneva se, da so koristni učinki olanzapina posledica zaviranja receptorjev za živčna prenašalca 5-hidroksitriptamin (imenovan tudi serotonin) in dopamin.
It is thought that these symptoms are due to an improvement in the body’s immune response, enabling the body to fight infections that may have been present with no obvious symptoms.
Prevladuje mnenje, da ti simptomi nastanejo zaradi izboljšanja imunskega odziva telesa, ki telesu omogoča, da se bori proti okužbam, ki so lahko prisotne brez očitnih simptomov.
It is thought that these symptoms are due to an improvement in the body’s immune response, enabling the body to fight infections that may have been present with no obvious symptoms.
Ti simptomi naj bi se pojavili zaradi izboljšanega imunskega odziva, ki telesu omogoča, da se bojuje proti okužbam, ki so bile lahko že prisotne brez očitnih simptomov.
It is thought that this process, at least in part, is responsible for the various cellular responses to interferon, including inhibition of virus replication in virus- infected cells, suppression of cell proliferation and such immunomodulating activities as enhancement of the phagocytic activity of macrophages and augmentation of the specific cytotoxicity of lymphocytes for target cells.
Menijo, da je ta proces vsaj deloma odgovoren za različne celične odzive na interferon, vključno z zaviranjem razmnoževanja virusa v okuženih celicah, supresijo celične proliferacije in imunomodulatornimi učinki, kot je okrepitev fagocitozne aktivnosti makrofagov in povečanje specifične citotoksičnosti limfocitov za tarčne celice.
It is thought that this process, at least in part, is responsible for the various cellular responses to interferon, including inhibition of virus replication in virus-infected cells, suppression of cell proliferation and such immunomodulating activities as enhancement of the phagocytic activity of macrophages and augmentation of the specific cytotoxicity of lymphocytes for target cells.
okuženih z virusi, supresijo celične proliferacije in različnimi oblikami imunomodulacijskega delovanja, kot je npr. okrepitev fagocitne aktivnosti makrofagov in povečanje specifične citotoksičnosti limfocitov za tarčne celice.
It is to be initiated in infants aged 5 weeks to 5 months (see section 4.2).
Zdravilo je indicirano pri dojenčkih, starih od 5 tednov do 5 mesecev (glejte poglavje »Odmerjanje in način uporabe«).
It is to be reconstituted and further diluted prior to intravenous administration, for instructions see section 6.6.
Za navodila glede rekonstitucije in nadaljnjega redčenja zdravila pred intravenskim infundiranjem glejte poglavje 6.6.
It is to be reconstituted only with one of the following:
Sme se ga pripraviti le z naslednjim:
It is to be used concomitantly with ciclosporin for microemulsion- and corticosteroid-based immunosuppression, in patients with panel reactive antibodies less than 80%, or in a triple maintenance immunosuppressive regimen containing ciclosporin for microemulsion, corticosteroids and either azathioprine or mycophenolate mofetil.
Namenjen je sočasni uporabi s ciklosporinom v mikroemulziji in kortikosteroidi za imunosupresijo pri bolnikih, ki imajo manj kot 80 % PRA (panel reactive antibodies), ali v trotirni vzdrževalni imunosupresivni shemi s ciklosporinom v mikroemulziji, kortikosteroidi in bodisi azatioprinom ali mofetilmikofenolatom.
It is unclear whether or not there is a direct association between pioglitazone and macular oedema but prescribers should be alert to the possibility of macular oedema if patients report disturbances in visual acuity; an appropriate ophthalmological referral should be considered.
Ni jasno, ali obstaja neposredna povezava med pioglitazonom in makularnim edemom, vendar pa morajo biti zdravniki pozorni na možnost makularnega edema, če bolnik poroča o motnjah vidne ostrine; up razmisliti je treba o pregledu priu oftalmologu.
It is uncommon, but cases of certain types of CANCER have been reported in patients treated with Cimzia or other TNF blockers.
V redkih primerih so poročali o določenih vrstah RAKA pri bolnikih, ki so uporabljali zdravilo Cimzia ali druge zaviralce TNF.
It is uncommon, but symptoms of a disease called lupus (for example persistent rash, fever, joint pain and tiredness) may occur.
V redkih primerih se lahko razvijejo simptomi bolezni, ki se imenuje lupus (npr. dalj časa trajajoč izpuščaj, zvišana telesna temperatura, bolečina v sklepih in utrujenost).
It is unknown if Jardiance is harmful to the unborn child.
Ni znano, ali zdravilo Jardiance škoduje nerojenemu otroku.
It is unknown if patients switching from these therapies to TYSABRI have an increased risk of PML, therefore these patients should be monitored more frequently (i.e. similarly to patients switching from immunosuppressants to TYSABRI).
Ni znano, ali je pri bolnikih, ki prehajajo s teh zdravljenj na zdravilo TYSABRI, tveganje za PML povečano, zato je treba te bolnike pogosteje spremljati (tj. podobno kot bolnike, ki prehajajo z imunosupresivov na zdravilo TYSABRI).
It is unknown if patients switching from these therapies to TYSABRI have an increased risk of PML, therefore these patients should be monitored more frequently (i.e. similarly to patients switching from immunosuppressants to TYSABRI, see MRI screening for PML).
Ni znano, ali je pri bolnikih, ki prehajajo s teh zdravljenj na zdravilo TYSABRI, tveganje za PML povečano, zato je treba te bolnike pogosteje spremljati (tj. podobno kot bolnike, ki prehajajo z imunosupresivov na zdravilo TYSABRI, glejte Pregled z MRS za PML).
It is unknown to what extent this decrease in haematological values was caused by the underlying prostate cancer and to what extent it was a consequence of androgen deprivation therapy.
Ni znano, do kakšne mere je to zmanjšanje hematoloških vrednosti povzročila osnovna bolezen, t.j. rak prostate, do kakšne mere pa je bilo zmanjšanje posledica zdravljenja z deprivacijo androgenov.
It is unknown whether 5-aminolaevulinic acid is excreted in human or animal milk.
Ni znano, ali se 5-aminolevulinska kislina izloča v materino ali živalsko mleko.
It is unknown whether aclidinium bromide and/or its metabolites are excreted in human milk.
Ni znano, ali se aklidinijev bromid in/ali njegovi presnovki izločajo v materino mleko.
It is unknown whether aflibercept is excreted in human milk.
Ni znano, ali se aflibercept izloča v materino mleko.
It is unknown whether aflibercept is excreted in human milk.
Ni znano, ali se aflibercept pri človeku izloča v materinem mleku.
It is unknown whether atazanavir or atazanavir metabolites are excreted in human milk.
Ni znano, če se atazanavir ali njegovi presnovki izločajo v materino mleko.
It is unknown whether axitinib is excreted in human milk.
Ni znano, ali se aksitinib izloča v materinem mleku.
It is unknown whether bosutinib and its metabolites are excreted in human milk.
Ni znano, ali se bosutinib in njegovi presnovki izločajo v mleko pri ljudeh.
It is unknown whether eculizumab is excreted into human milk.
Ni znano, ali se ekulizumab izloča v materino mleko.
It is unknown whether EVOTAZ or its active components are excreted in human milk.
Ni znano, ali se zdravilo EVOTAZ ali njegovi zdravilni učinkovini pri ljudeh izločajo v materino mleko.
It is unknown whether exenatide is excreted in human milk.
Ni znano, ali se eksenatid izloča v materino mleko.
It is unknown whether fesoterodine/metabolites are excreted into human milk; therefore, breast-feeding is not recommended during treatment with TOVIAZ.
Ni znano, ali se fesoterodin/presnovki izločajo v materino mleko; med zdravljenjem z zdravilom TOVIAZ dojenje zato ni priporočljivo.
It is unknown whether Fexeric has any effect on unborn babies.
Ni znano, ali ima zdravilo Fexeric učinke na nerojenega otroka.
It is unknown whether Fexeric may pass through breast milk and affect your baby.
Ni znano, ali lahko zdravilo Fexeric prehaja v materino mleko in vpliva na otroka.
It is unknown whether filgrastim is excreted in human breast milk.
Ni znano ali se filgrastim pri človeku izloča v materino mleko.
It is unknown whether filgrastim passes over to the breast milk.
Ni znano ali se filgrastim izloča v materino mleko.
It is unknown whether guanfacine and its metabolites are excreted in human milk.
Ni znano, ali se gvanfacin in njegovi presnovki izločajo v materino mleko.
It is unknown whether ipilimumab is secreted in human milk.
Ni znano, ali se ipilimumab izloča v materino mleko.
It is unknown whether Nimenrix is excreted in human milk.
Ni znano, ali se cepivo Nimenrix pri človeku izloča v materinem mleku.
It is unknown whether nivolumab is secreted in human milk.
Ni znano, ali se nivolumab izloča v materino mleko.
It is unknown whether ofatumumab is excreted in human milk, however human IgG is secreted in human milk.
Ni znano, ali se ofatumumab izloča v materinem mleku, se pa v materinem mleku izloča človeški IgG.
It is unknown whether olaparib/or its metabolites are excreted in human milk.
Ni znano, ali se olaparib ali njegovi presnovki izločajo v materinem mleku.
It is unknown whether omalizumab is excreted in human milk.
Ni znano, ali se omalizumab izloča v materino mleko.
It is unknown whether ONIVYDE or its metabolites are excreted into human milk.
Ni znano, ali se zdravilo ONIVYDE ali njegovi presnovki izločajo v materino mleko.
It is unknown whether panitumumab is excreted in human breast milk.
Ni znano, ali se panitumumab pri človeku izloča v materinem mleku.
It is unknown whether patients with such conditions could receive subtherapeutic saquinavir levels.
Ni znano, ali bi bolniki s takimi stanji lahko prejeli količine sakvinavirja, ki so pod terapevtskimi koncentracijami.
It is unknown whether pirfenidone or its metabolites are excreted in human milk.
Ni znano, ali se pirfenidon oz. njegovi presnovki izločajo v materino mleko.
It is unknown whether Pixuvri/metabolites are excreted in human milk.
Ni znano, ali se zdravilo Pixuvri/presnovki izločajo v materino mleko.
It is unknown whether Renvela has any affect on unborn babies.
Ni znano, ali zdravilo Renvela vpliva na nerojenega otroka.
It is unknown whether Renvela may pass through breast milk and affect your baby.
Ni znano, ali zdravilo Renvela prehaja skozi materino mleko in vpliva na otroka.
It is unknown whether Sevelamer carbonate Zentiva has any effect on unborn babies.
Ni znano, ali zdravilo Sevelamer carbonate Zentiva vpliva na nerojenega otroka.
It is unknown whether Sevelamer carbonate Zentiva may pass through breast milk and affect your baby.
Ni znano, ali zdravilo Sevelamer carbonate Zentiva prehaja skozi materino mleko in vpliva na otroka.
It is unknown whether sofosbuvir, metabolites of sofosbuvir or velpatasvir are excreted in human milk.
Ni znano, ali se sofosbuvir in njegovi presnovki ali velpatasvir izločajo v materino mleko.
It is unknown whether sonidegib is contained in semen.
Ni znano, ali je sonidegib prisoten v spermi.
It is unknown whether telavancin is excreted in human breast milk.
Ni znano, ali se telavancin pri ljudeh izloča v materino mleko.
It is unknown whether the
Ni znano, ali tudi kombinacija
It is unknown whether the amount of estradiol in IOA is sufficient to maintain adequate levels of estradiol in adolescents, especially for bone mass accrual (see section 5.2).
Ni znano, če količina estradiola v zdravilu IOA zadostuje za vzdrževanje ustrezne ravni estradiola pri mladostnikih, še posebej za prirastek kostne mase (glejte poglavje 5.2).
It is unknown whether the combination of tipranavir with ritonavir might cause a larger increase in fluticasone exposure.
Ni znano, ali bi lahko kombinacija tipranavirja z ritonavirjem močneje povečala
It is unknown whether the increased metabolite exposure in endstage renal disease subjects could give rise to adverse effects but no pharmacological activity of the metabolite has been identified.
Ni znano, ali povečana izpostavljenost presnovku pri bolnikih s končno ledvično odpovedjo povzroči tudi povečanje neželenih učinkov, čeprav niso opazili farmakološke aktivnosti presnovkov.
It is unknown whether the reduced pup growth is caused by reduced pup milk intake due to a direct GLP­1 effect or reduced maternal milk production due to decreased caloric intake.
Ni znano, ali je upočasnjena rast mladičev posledica zmanjšanja hranjenja mladičev z materinim mlekom zaradi neposrednega vpliva GLP-1 ali posledica manjšega nastajanja mleka pri materi zaradi manjšega kaloričnega vnosa.
It is unknown whether the use of interleukin-1 (IL-1) inhibitors such as Ilaris increases the risk of reactivation of tuberculosis.
Ni znano, ali uporaba zaviralcev interlevkina-1 (zaviralcev IL-1), kot je zdravilo Ilaris, povečuje tveganje za reaktivacijo tuberkuloze.
It is unknown whether there is a change in the plasma protein binding in hepatically impaired subjects.
Ni znano, ali se pri preiskovancih z okvaro jeter spremeni vezava na plazemske beljakovine.
It is unknown whether there is a change in the plasma protein binding in renally impaired subjects.
Ni znano, ali se pri preiskovancih z okvaro ledvic spremeni vezava na plazemske beljakovine.
It is unknown whether there is an increased risk of myopathy in other Asian patients treated with Pelzont co-administered with simvastatin or ezetimibe/simvastatin.
Ni znano, ali je tveganje za miopatijo povečano tudi pri drugih azijskih bolnikih, zdravljenih z zdravilom Pelzont in s simvastatinom ali z ezetimibom/simvastatinom.
It is unknown whether there is an increased risk of myopathy in other Asian patients treated with Tredaptive co-administered with simvastatin or ezetimibe/simvastatin.
Ni znano, ali je tveganje za miopatijo povečano tudi pri drugih azijskih bolnikih, zdravljenih z zdravilom Tredaptive in s simvastatinom ali z ezetimibom/simvastatinom.
It is unknown whether there is an increased risk of myopathy in other Asian patients treated with Trevaclyn co-administered with simvastatin or ezetimibe/simvastatin.
Ni znano, ali je tveganje za miopatijo povečano tudi pri drugih azijskih bolnikih, zdravljenih z zdravilom Trevaclyn in s simvastatinom ali z ezetimibom/simvastatinom.
It is unknown whether this leukemogenic effect is secondary to hydroxycarbamide or is associated with the patient’s underlying disease.
Ni znano, če je levkemogenski učinek sekundarna posledica hidroksikarbamida ali pa je povezan z bolnikovo boleznijo.
It is unknown whether tolvaptan is excreted in human breast milk.
Ni znano, ali se tolvaptan izloča v mleko pri ljudeh.
It is unknown whether vedolizumab is excreted in human milk or absorbed systemically after ingestion.
Ni znano, ali se vedolizumab izloča v materino mleko, ali po zaužitju absorbira sistemsko.
It is unlikely that ANORO will affect your ability to drive or use machines.
Ni verjetno, da bi zdravilo ANORO vplivalo na vašo sposobnost upravljanja vozil in strojev.
It is unlikely that daptomycin will inhibit or induce the metabolism of medicinal products metabolised by the P450 system.
Tako ni verjetno, da bi daptomicin lahko zaviral ali induciral presnovo zdravil, ki se presnavljajo s pomočjo sistema P450.
It is unlikely that Hirobriz Breezhaler will affect your ability to drive and use machines.
Po vsej verjetnosti zdravilo Hirobriz Breezhaler ne vpliva na vašo sposobnost upravljanja vozil in strojev.
It is unlikely that LAVENTAIR will affect your ability to drive or use machines.
Ni verjetno, da bi zdravilo LAVENTAIR vplivalo na vašo sposobnost upravljanja vozil in strojev.
It is unlikely that Onbrez Breezhaler will affect your ability to drive and use machines.
Po vsej verjetnosti zdravilo Onbrez Breezhaler ne vpliva na vašo sposobnost upravljanja vozil in strojev.
It is unlikely that Opgenra will affect the ability to drive and use machines
Ni verjetno, da bi zdravilo Opgenra vplivalo na sposobnost upravljanja vozil in strojev.
It is unlikely that Oslif Breezhaler will affect your ability to drive and use machines.
Po vsej verjetnosti zdravilo Oslif Breezhaler ne vpliva na vašo sposobnost upravljanja vozil in strojev.
It is unlikely that patients with inadequate on-treatment virologic response will achieve a sustained virologic response (SVR), therefore discontinuation of treatment is recommended in these patients.
Ker je malo verjetno, da bodo bolniki z nezadostnim virološkim odzivom dosegli trajni virološki odziv (SVR – sustained virologic response), je priporočljivo, da tem bolnikom zdravljenje ukinete.
It is unlikely that patients with inadequate on-treatment virologic response will achieve a sustained virologic response (SVR); therefore discontinuation of treatment is recommended in these patients.
Malo verjetno je, da bi bolniki z nezadostnim virusnim odzivom med zdravljenjem dosegli trajen virološki odziv (SVR - sustained virologic response), zato je pri teh bolnikih zdravljenje priporočljivo ukiniti.
It is unlikely that the pharmacokinetics of ataluren are significantly affected by UTG1A9 polymorphisms in a Caucasian population.
Verjetnost, da bi imeli polimorfizmi UTG1A9 pri populaciji belcev pomembnejši vpliv na farmakokinetiko atalurena, je majhna.
It is unlikely that this medicine would pass into the mother’s milk.
Malo verjetno je, da bi to zdravilo prehajalo v materino mleko.
It is unlikely that Xolair will affect your ability to drive and use machines.
Malo verjetno je, da bi zdravilo Xolair vplivalo na vašo sposobnost upravljanja vozil in strojev.
It is unlikely that you will forget to take Aloxi, however, if you think you have forgotten to take your dose, tell your doctor immediately.
Najbrž ne boste pozabili vzeti zdravila Aloxi, če pa vseeno mislite, da ste pozabili vzeti odmerek, takoj obvestite svojega zdravnika.
It is unsure if stroke is related to receiving Thyrogen.
Ni jasno, ali je kap povezana s prejemanjem zdravila Thyrogen.
It is used after at least one other treatment has failed; small cell lung cancer, when the cancer has relapsed (come back).
Uporablja se, če je bil pred tem neučinkovit vsaj en drug način zdravljenja; ob relapsu drobnoceličnega pljučnega raka (ponovitvi bolezni).
It is used after at least one other treatment has failed; small cell lung cancer, when the cancer has relapsed (come back).
Uporablja se, če je bil pred tem neučinkovit vsaj en drug način zdravljenja; za zdravljenje ob relapsu drobnoceličnega pljučnega raka (ponovitvi bolezni).
It is used as a light- activated medicinal product (photosensitiser).
Uporablja se kot zdravilo, ki se aktivira s svetlobo (fotosenzitizator).
It is used as a maintenance (regular) treatment to relieve the symptoms of chronic obstructive pulmonary disease (COPD) in adults.
Uporablja se kot vzdrževalno (redno) zdravljenje za lajšanje simptomov kronične obstruktivne pljučne bolezni (KOPB) pri odraslih.
It is used as an add- on to existing treatment in patients aged 12 years or over who do not respond to treatment with antihistamines.
Uporablja se kot dodatek k obstoječemu zdravljenju pri bolnikih, starejših od 12 let, ki se ne odzivajo na zdravljenje z antihistaminiki.
It is used as part of a programme that also includes controlling the dog’s intake of food.
Uporablja se kot del programa, ki obsega tudi nadzor prehranskega vnosa.
It is used by adults, adolescents and children 3 months of age and older and weighing at least 3.5 kg.
Uporablja se pri odraslih, mladostnikih in otrocih, starih 3 mesece ali več s telesno maso najmanj 3,5 kg.
It is used by people with type 2 diabetes. (This kind of diabetes is also called non-insulin-dependent diabetes mellitus.)
Uporabljajo ga ljudje s sladkorno boleznijo tipa 2. (Ta vrsta sladkorne bolezni se imenuje tudi insulinsko neodvisni diabetes mellitus.)
It is used during the patients’ first ‘remission’ (a period without symptoms of the disease after the first course of treatment).
Uporablja se ob prvi remisiji (obdobju brez simptomov bolezni po prvemu zdravljenju).
It is used either on its own or in combination with another medicine containing dabrafenib to treat a type of skin cancer called melanoma that has a particular change (mutation) in a gene called BRAF, and that has spread to other parts of the body, or cannot be removed by surgery.
Uporabljamo ga bodisi samostojno ali v kombinaciji z drugim zdravilom, ki vsebuje dabrafenib, za zdravljenje vrste kožnega raka, imenovanega melanom, ki ima posebno spremembo (mutacijo) gena BRAF in ki se je razširil v druge dele telesa, ali ga ni mogoče odstraniti z operacijo.
It is used either on its own or in combination with another medicine containing trametinib in adults to treat a type of skin cancer called melanoma, that has a particular change (mutation) in a gene called BRAF, and that has spread to other parts of the body or cannot be removed by surgery
Uporablja se bodisi samostojno ali v kombinaciji z drugim zdravilom, ki vsebuje trametinib, pri odraslih za zdravljenje vrste kožnega raka, imenovanega melanom, ki ima posebno spremembo (mutacijo) gena BRAF, in se je razširil v druge dele telesa ali ga ni mogoče odstraniti z operacijo.
It is used for brain scans in adult patients with memory problems so that doctors can see whether or not they have significant amounts of β-amyloid plaques in the brain. β-amyloid plaques are deposits sometimes present in the brains of people with dementias (such as Alzheimer’s disease, Lewy body dementia and Parkinson’s disease dementia) and some elderly people with no symptoms.
Uporablja se pri slikanju možganov odraslih bolnikov, ki imajo težave s spominom, tako da lahko zdravniki vidijo, ali imajo bolniki morda v možganih znatne količine β-amiloidnih leh. β-amiloidne lehe so obloge, ki so včasih prisotne v možganih oseb z demencami (kot so Alzheimerjeva bolezen, demenca z Lewyjevimi telesci in demenca pri Parkinsonovi bolezni) ter pri nekaterih asimptomatskih starejših osebah.
It is used for the long-term treatment of pulmonary arterial hypertension (PAH), a condition in which there is abnormally high blood pressure in the arteries of the lungs, causing symptoms such as breathlessness and fatigue.
Uporablja se za dolgotrajno zdravljenje pljučne arterijske hipertenzije (PAH), tj. bolezni, za katero je značilen nenormalno visok krvni tlak v pljučnih arterijah, ki povzroča simptome, kot sta zasoplost in utrujenost.
It is used for the regular treatment of asthma in adults and children aged 12 years and above whose disease is not adequately controlled despite treatment with other asthma medicines called corticosteroids and ‘short-acting beta-2 agonists’ taken by inhalation and for whom a combination product is considered appropriate.
Uporablja se za redno zdravljenje astme pri odraslih in otrocih, starejših od 12 let, pri katerih kljub zdravljenju z drugimi zdravili proti astmi, imenovanimi kortikosteroidi in kratkodelujoči agonisti beta-2 adrenergičnih receptorjev, ki jih bolniki jemljejo z inhalacijo, bolezni ni mogoče ustrezno obvladati in pri katerih je primerna uporaba kombiniranega zdravila.
It is used for the treatment and prevention of bleeding in patients with haemophilia A (an inherited bleeding disorder caused by lack of factor VIII).
Uporablja se za zdravljenje in preprečevanje krvavitev pri bolnikih s hemofilijo A (prirojeno motnjo strjevanja krvi zaradi pomanjkanja faktorja VIII).